NCT01337427: Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis |
|
|
| Withdrawn | 3 | 0 | US | BIIB017, PEGylated Interferon beta-1a, PEG IFN β-1a | Johns Hopkins University, Biogen | Relapsing Remitting Multiple Sclerosis | 08/13 | 08/13 | | |
| Completed | 3 | 1077 | US, Canada, Europe, RoW | peginterferon beta-1a, PEGylated Interferon beta-1a, Plegridy, PEG IFN β-1a, BIIB017 | Biogen | Relapsing Multiple Sclerosis | 10/15 | 10/15 | | |
NCT01939002: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) |
|
|
| Completed | 3 | 251 | US | BIIB017, Plegridy, peginterferon beta-1a, PEGylated interferon beta-1a, PEG IFN β-1a, naproxen, naproxen sodium, Aleve, NSAID, long-acting nonsteroidal anti-inflammatory drug | Biogen | Relapsing Multiple Sclerosis | 10/15 | 11/15 | | |
